Table 2.
Targeting of KRAS related molecules in cancer via CRISPR systems (information is provided first based on cancer type, then in chronological order.)
| CRISPR system | Cancer type | Targeted molecules | Cell type | Animal model | Publication year | Reference |
|---|---|---|---|---|---|---|
| CRISPR/Cas9 | Lung | MUC1-C | A549/KRAS(G12S), H460/KRAS(Q61H), H358/KRAS(G12C), H441/KRAS(G12V), H2009/KRAS(G12A), H1975/EGFR(L858R/T790M), PC9GR/EGFR(delE746_A750), H838s(mutant p53) and HEK293T | NCR nu/nu | 2016 | [127] |
| CRISPR/Cas9 | Lung | KEAP-1 | A549, H2030, H2009, KP1, KP2 and KPK | KrasLSL−G12D/+; p53flox/flox (KP) | 2017 | [128] |
| CRISPR/Cas9 | Lung | KEAP-1 | NCI-H1299, HCC364, NCI-H1975, and HCC827 |
Nude mice HCC827 KEAP1KO |
2017 | [131] |
| CRISPR/Cas9 | Lung | Smarca4 (Brg1), Arid1a and Setd2 | HEK293 FT | C567B6/129Sv4: KrasLSL−G12D and KrasLSL−G12D;p53flox/flox | 2017 | [132] |
| CRISPR/Cas9 | Lung | MEK-ERK-PI3K pathways | HCT116, SW620, CRC119 and CRC240 | NOD/SCID gamma mice or nude mice | 2017 | [133] |
| CRISPR/Cas9 | Lung | PI3K pathway | HCT116, DLD1, CT26 and AALE | BALB/c mice | 2017 | [134] |
| CRISPR/Cas9 | Lung | Utx | KrasG12D/+ MEFs, KP cells, KPU cells, and HEK-293 T | KrasG12D/+, Trp53L/L, Lkb1L/L, and UtxL/L mice | 2018 | [135] |
| CRISPR/Cas9 | Lung | MAPK7 | MOR (ECACC), NCI-H2122 (ATCC), A549 (ATCC), NCI-H441 (ATCC) | NCr nu/nu mice | 2018 | [143] |
| CRISPR/Cas9 | Lung | NF1 |
KP.1, KP.2, LKR10 and LKR13 mouse KRAS‐mutant/TP53‐WT/NF1‐WT (PDK), KRAS‐mutant/TP53‐WT/NF1‐mutant (PDKN1 and PDKN2) human |
LSL‐Kras G12D; Trp53 flox (KP) mice C57BL/6–129/Sv | 2019 | [138] |
| CRISPR/Cas9 | Lung | STK11/LKB1 and SIK1, SIK3 | A549, 634 T KP, VB-mouse lung tumor-derived KP and KPSik1 cells |
Kras (KrasLSLG12D/ + ; R26LSL;luc/luc); KL (KrasLSLG12D/ + ; Lkb1fl/fl;R26LSL;luc/luc) KP (KrasLSLG12D/ + ; p53fl/fl;R26LSL;luc/luc) KPL (KrasLSLG12D/ + ; Lkb1fl/fl;p53fl/fl;R26LSL;luc/luc); Sik1fl/fl and Sik2fl/fl mice |
2019 | [139] |
| CRISPR/Cas9 | Lung | STK11/LKB1 and SIK family | A549, H2122, H2126, H1650 | KrasLSL−G12D, p53flox, Lkb1flox, H11LSL−Cas9 and Rosa26LSL−tdTomato mice | 2019 | [172] |
| CRISPR/Cas9 | Lung | PCDH7 | HBECs, H1944 |
PCDH7 transgenic mice C57BL/6 J strain KrasLSL−G12D; PCDH7LSL/LSL; KrasLSL−G12D; Tp53fl/fl |
2019 | [141] |
| CRISPR/Cas9 |
Lung Pancreas |
SHOC2 | CFPAC-1, A549, NCI-H23, KP4, MIA PaCa-2, NCI-H2030, Panc 10.05, HCC364, NCI-H1299, HCT116, LOVO, PA-TU-8902, NCI-H1975, NCI-H2009, SU.86.86, MDA-MB-157, and MDA-MB-436 | SCID Hairless Outbred (SHO) mice | 2019 | [142] |
| CRISPR/Cas9 | Lung | EGFR | A549 | n/a | 2020 | [144] |
| CRISPR/Cas9 | Lung | STK11 and PTEN | n/a | n/a | 2021 | [151] |
| CRISPR/Cas9 | CRC | Apc and Trp53 | Lgr5 + stem cells murine AKP and human LS174 | Apcfl/fl, KrasLSL−G12D/+, VillinCreER,, Lgr5eGFP−CreE, Lgr5CreER, Rosa26LSL−Cas9−eGFP and Rosa26LSL−tdTomato | 2017 | [145] |
| CRISPR/Cas9 | CRC | ERN1-JNK-JUN | HEK293 | n/a | 2018 | [146] |
| CRISPR/Cas9 | CRC | TGFBR2 | HepG2 and HEK293T | NOD scid gamma (NSG) mice | 2020 | [147] |
| CRISPR/Cas9 | Pancreas | PI3K | PACO9 and PACO19 | LSL-Kras G12D; p53 flox/flox; Pdx1-CreER, LSL-Kras G12D; p53 R172H/WT; Pdx1-Cre (KPC) and A13 clones | 2017 | [110] |
| CRISPR/Cas9 | Pancreas | GALNT3 and B3GNT3 | SW1990, Capan1, NSP and SP | KrasG12D; Pdx-1-Cre (KC) and KrasG12D; p53R172H; Pdx-1-Cre (KPC) | 2018 | [148] |
| CRISPR/Cas9 | Pancreas | ISG15 | Panc02 | C57BL/6 | 2019 | [149] |
| CRISPR/Cas9 | Pancreas | PRKD1 | Panc-1, WI-38 | PRKD1KO, KC, PRKD1KO−KC, p48Cre, LSL-KrasG12D and NSG | 2020 | [150] |